Results and status after the first periodic report

Date: 01/10/2013
Location: QIM facilities, Copenhagen (Denmark)


  • The tissue viability sensor has been selected and T-SCI needs have been gathered. On the one hand, 10 users were involved to test (Task 1.1) the reliability, robustness and the possibility to detect risk of PU of the following sensors: laser Doppler, pulse oximetry, transcutaneous pO2 (all of them used for clinical purposes) and impedance spectrometry. Moreover, this was complemented with a comparative of cost and easy to embed on smart textile. Finally, the impedance spectrometry was selected to monitor tissue status because it was reliable and robust as the other sensor but it was the cheapest and the easiest to embed sensor (Internal report T1.1).


  • On the other hand, three tasks were performed to characterize users:
    1. Firstly, 20 healthy users were involved to test healthy tissue values and detect their repositioning strategies. Healthy thresholds of impedance and pressure signals have been defined as well the effect of personal factors (body mass index, gender and age) on these signals (D1.1). Moreover, the main repositioning strategies and its frequency have been detected.
    2. Secondly, 20 SCI users were involved to test their tissue values and the effect of PUMA strategies. The differences between healthy and SCI of baselines values and tissue response to pressure has been assessed. Moreover, the effect of the repositioning strategies has been checked, as well anthropometric dimensions have been gathered (D1.2).
    3. Thirdly, SCI users, caregivers and professionals were involved using People Driven Innovation methodology. The main scenarios of use and the PUMA actuation strategy (tilt, cushion, FES) for each identified scenarios of use have been identified . Moreover, the preferences about the PUMA system have been obtained. This information has been ordered and prioritized (D1.3) in order to offer useful information for the development of the PUMA system.


The requirements of PUMA components were defined.

  • Firstly, the standard requirements, technical and security tests, and risk analysis to achieve CE mark and medical certification were provided for each component (D2.1).
  • Secondly, the requirements of smart short (D2.2), repositioning systems (D2.3), user interface (D2.4) and control system (D2.5) were defined. These requirements were based on users needs (D1.1-D1.3) and technical requirements and manufacture boundaries provided by Qimova, Berkelbike and Smartex.
  • The set of requirements cover from functional and technical requirements to usability and aesthetic requirements.
  • This set of deliverable and the conceptual design (D2.6) will be the basis for the development of each component of PUMA system.



The first work has been done to translate the results of tests with healthy and T-SCI users, to the preliminary processing and decision making algorithms.


The inclusion/exclusion criteria and the test protocols and metrics to involve users were defined (D7.1). This deliverable will be improved based on the first prototypes. Moreover, protocols and procedure were provided to accomplish ethical requirements.

The website of the project has been prepared ( The website consists of two main parts, an public one with general information of the project, and a private one where only the members of the project can access. Anyone interested in further information of the PUMA product, can access to the public part of the website.